May 27, 2008
An independent Data and Safety Monitoring Board (DSMB) has determined that the experimental, once-daily antiretroviral drug regimen of emtricitabine, atazanavir and didanosine enteric-coated (ddI-EC) is inferior to a standard antiretroviral drug regimen and therefore should be discontinued in an ongoing clinical trial. The National Institute of Allergy and Infectious Diseases (NIAID), the part of the National Institutes of Health that oversees the trial, concurs with this recommendation and has stopped this component of the study.
This development arose from the DSMBs recent review of safety and efficacy data from a Phase IV clinical trial sponsored by NIAID. The trial is examining whether certain regimens of antiretrovirals taken once a day are at least as good as a standard antiretroviral regimen containing a drug combination taken twice a day. The study involves 1,571 HIV-infected volunteers on four continents who were randomly assigned to take one of three drug regimens:
Those participants who have been taking emtricitabine + atazanavir + ddI-EC are being advised to consult their study physicians to determine to which alternative regimen they should switch and how best to proceed with their antiretroviral therapy. The study team is continuing follow-up of all volunteers, including those in the second group who are switching to a different antiretroviral drug regimen.
The study team finished enrolling all volunteers in July 2007 and is gathering data through follow-up visits with the study participants, who are located in Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, the United States and Zimbabwe. The study is known as ACTG 5175 and is titled "Evaluation of Once-Daily PI and NNRTI Regimens as Initial HIV Therapy in Individuals from Resource-Limited Settings."
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.